[C#199200273:Galderma]has received US FDA approval for Vectical (calcitriol) 3μg/g ointment, for use in the treatment of mild-to-moderate plaque psoriasis in adults. It will be launched in the first quarter of this year. The product is already marketed in the UK (as Silkis) and elsewhere.
Galdermahas received US FDA approval for Vectical (calcitriol) 3μg/g ointment, for use in the treatment of mild-to-moderate plaque psoriasis in adults. It will be launched in the first quarter of this year. The product is already marketed in the UK (as Silkis) and elsewhere.
Vectical is the only calcitriol (vitamin D3) ointment available in the US, and Galderma claims that it is one of...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
